JP2010501164A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501164A5
JP2010501164A5 JP2009524844A JP2009524844A JP2010501164A5 JP 2010501164 A5 JP2010501164 A5 JP 2010501164A5 JP 2009524844 A JP2009524844 A JP 2009524844A JP 2009524844 A JP2009524844 A JP 2009524844A JP 2010501164 A5 JP2010501164 A5 JP 2010501164A5
Authority
JP
Japan
Prior art keywords
antibody
seq
identity
cdr2
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009524844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501164A (ja
JP5162587B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2007/001207 external-priority patent/WO2008022390A1/en
Publication of JP2010501164A publication Critical patent/JP2010501164A/ja
Publication of JP2010501164A5 publication Critical patent/JP2010501164A5/ja
Application granted granted Critical
Publication of JP5162587B2 publication Critical patent/JP5162587B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009524844A 2006-08-22 2007-08-22 改良された特性を持つ坑−C5aR抗体 Expired - Fee Related JP5162587B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83963406P 2006-08-22 2006-08-22
US60/839,634 2006-08-22
PCT/AU2007/001207 WO2008022390A1 (en) 2006-08-22 2007-08-22 Anti-c5ar antibodies with improved properties

Publications (3)

Publication Number Publication Date
JP2010501164A JP2010501164A (ja) 2010-01-21
JP2010501164A5 true JP2010501164A5 (enExample) 2010-09-30
JP5162587B2 JP5162587B2 (ja) 2013-03-13

Family

ID=39106388

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009524844A Expired - Fee Related JP5162587B2 (ja) 2006-08-22 2007-08-22 改良された特性を持つ坑−C5aR抗体

Country Status (15)

Country Link
US (1) US8337852B2 (enExample)
EP (2) EP2051997B1 (enExample)
JP (1) JP5162587B2 (enExample)
KR (1) KR20090053899A (enExample)
CN (2) CN101506237B (enExample)
AU (1) AU2007288118A1 (enExample)
BR (1) BRPI0715703A2 (enExample)
CA (1) CA2660156A1 (enExample)
ES (1) ES2570153T3 (enExample)
IL (1) IL196960A0 (enExample)
MX (1) MX2009001914A (enExample)
NO (1) NO20091181L (enExample)
RU (1) RU2009110154A (enExample)
WO (1) WO2008022390A1 (enExample)
ZA (1) ZA200900954B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071096B2 (en) 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
CA2714296A1 (en) 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies
AU2011245117B2 (en) 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
US11130801B2 (en) * 2011-01-13 2021-09-28 Case Western Reserve University Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies
ES2929575T3 (es) * 2011-06-06 2022-11-30 Novo Nordisk As Anticuerpos terapéuticos
KR102006997B1 (ko) * 2012-07-03 2019-08-02 한국생명공학연구원 IgG Fc 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
JP6923212B2 (ja) * 2016-02-17 2021-08-18 国立大学法人 東京医科歯科大学 動脈硬化性疾患の発症の予測因子および検査方法
CN106614260B (zh) * 2016-09-06 2019-11-08 广东省人民医院 一种C5aR基因敲除小鼠cGVHD模型的建立方法
DK3411400T3 (da) * 2017-04-03 2021-10-11 Inflarx Gmbh Behandling af inflammatoriske sygdomme med hæmmere af c5a-aktivitet
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
AU2020438234A1 (en) 2020-03-27 2022-09-29 Inflarx Gmbh Inhibitors of C5a for the treatment of corona virus infection
TW202208427A (zh) 2020-05-06 2022-03-01 德商因夫萊亞斯有限公司 人源化抗c5a抗體
US11912781B2 (en) 2021-01-13 2024-02-27 Visterra, Inc. Humanized complement 5A receptor 1 antibodies and methods of use thereof
US12180274B2 (en) 2023-05-26 2024-12-31 Inflarx Gmbh Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4098876A (en) * 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279582A3 (en) * 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH02262599A (ja) 1989-01-03 1990-10-25 Merck & Co Inc ヒト多形核白血球からの精製C5aレセプター
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5284746A (en) * 1990-02-08 1994-02-08 Zymogenetics, Inc. Methods of producing hybrid G protein-coupled receptors
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5194594A (en) * 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2145278C (en) 1992-09-25 2009-03-10 Commonwealth Scientific And Industrial Research Organisation Target binding polypeptide
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US5480974A (en) * 1993-06-18 1996-01-02 The Scripps Research Institute Antibodies to human C5a receptor
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5861272A (en) * 1995-06-02 1999-01-19 Human Genome Sciences, Inc. C5A receptor
JPH08109200A (ja) 1994-08-19 1996-04-30 Takeda Chem Ind Ltd 抗C5aレセプター抗体、その製造法および用途
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
EP0832231A2 (en) 1995-06-05 1998-04-01 Incyte Pharmaceuticals, Inc. A C5a-LIKE SEVEN TRANSMEMBRANE RECEPTOR
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
AU6035398A (en) 1997-01-31 1998-08-25 Incyte Pharmaceuticals, Inc. Human c5a-like receptor
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
WO2002038767A2 (en) 2000-11-07 2002-05-16 Genetics Institute, Llc. G protein-coupled receptor protein and nucleic acid molecules and uses therefor
WO2002061087A2 (en) 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
MXPA04001301A (es) * 2001-08-17 2004-07-08 Tanox Inc Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b.
DE60234944D1 (de) 2001-09-27 2010-02-11 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodiered assayverfahren
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US8071096B2 (en) * 2002-01-25 2011-12-06 G2 Therapies Ltd Anti-C5aR antibodies and uses thereof
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
AU2004304665B2 (en) * 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
WO2006037604A1 (en) * 2004-10-01 2006-04-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel antibodies directed to the mammalian eag1 ion channel protein
WO2008022391A1 (en) 2006-08-22 2008-02-28 G2 Inflammation Pty Ltd Method for producing antibodies
ZA200900954B (en) 2006-08-22 2010-05-26 G2 Inflammation Pty Ltd Ant-C5aR antibodies with improved properties
CA2714296A1 (en) * 2008-02-20 2009-08-27 G2 Inflammation Pty Ltd Humanized anti-c5ar antibodies

Similar Documents

Publication Publication Date Title
RU2009110154A (ru) АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
RU2434881C2 (ru) Il-13 связывающие агенты
CN108271359B (zh) 结合ctla4的抗体治疗剂
KR101853278B1 (ko) 치료학적 dll4 결합 단백질
AU2014361473B2 (en) PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP2009517057A5 (enExample)
CN112585165A (zh) 优化的抗tl1a抗体
WO2018137576A1 (zh) 抗pd-1单克隆抗体及其制备方法和应用
RU2014131317A (ru) Связывающие mica агенты
CN112969719A (zh) 双功能融合蛋白及其医药用途
JP2022527151A5 (enExample)
JP6105146B2 (ja) Pan−ELR+CXCケモカイン抗体
EP3683234A1 (en) Il-6r antibody and antigen binding fragment thereof and medical use
CN102027015A (zh) 抗cxcr4抗体
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
JP2018510617A5 (enExample)
RU2012107286A (ru) Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2
TW200836763A (en) Pegylated Aβ FAB
CN104662153A (zh) 针对转运体的抗体及其用途
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2010527939A5 (enExample)
JP2017507131A5 (enExample)
HUE032431T2 (en) BMP-6 antibodies
JP2005535562A5 (enExample)
CN112480259B (zh) 抗tnfr2抗体及其用途